Resilience Fund: Strand 2 to support Health and Lifesciences II Project -103944

创伤性伤害是一个未得到满足的主要临床需求，也是世界各地年轻人死亡和残疾的主要原因。创伤治疗和管理是非常复杂、昂贵和资源密集的。这是一个快速变化的环境，临床医生不断寻求最佳治疗方法来管理和稳定病情严重的患者。在这些患者中，失血导致正常的凝血因子水平紊乱，导致凝血功能障碍。这种有缺陷的凝血过程导致持续的不受控制的出血，这有很高的死亡率。这个合作研究项目——与高地生物科学有限公司（HBL）、英国国立卫生研究院伦敦体外诊断合作社（LIVDC）、帝国理工学院医疗保健NHS信托、苏塞克斯大学和大学医院苏塞克斯NHS基金会信托合作——将开发新的生物传感器产品技术。这种新设备将在几分钟内将患者的凝血状态结果送到患者的床边，从而指导创伤患者选择最佳治疗和管理方案，并减少除受影响最严重的患者外的所有患者的输血需求和输血次数。

Traumatic injuries are a major unmet clinical need and the leading cause of death and disability among young people around the world. Trauma treatment and management is very complex, costly and resource-intense. It is a fast-moving environment where clinicians constantly seek the best treatment to manage and stabilise very sick patients. In these patients, blood loss causes usual levels of clotting factors to be deranged leading to coagulopathy. This defective clotting processes results in continued uncontrolled bleeding which has a high risk of mortality. This collaborative research project -- with Highland Biosciences Limited (HBL), the NIHR London In-Vitro Diagnostic Co-operative (LIVDC), Imperial College Healthcare NHS Trust, University of Sussex and University Hospitals Sussex NHS Foundation Trust - will develop new biosensor product technology. The new device will guide the selection of the best treatment and management regime for trauma patients by bringing results of a patient's clotting status to the patient's bedside within a few minutes and reduce the need for and number of blood transfusions in all but the most severely affected patients.